Skip to main content
SpringerLink
Log in

Association Between a Single Nucleotide Polymorphism in the TP53 Region and Risk of Ovarian Cancer

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

TP53 is known as a tumor suppressor gene involved in cell cycle regulation. Many previous epidemiological and clinical studies have evaluated the effects of rs1042522 polymorphism on risk of ovarian cancer. But the results are conflicting and heterogeneous. The primary objective of this study was to examine whether rs1042522 polymorphism is associated with ovarian cancer risk. We performed a comprehensive meta-analysis of 19 case–control studies that analyzed rs1042522 polymorphism in ovarian cancer risk. Odds ratios (ORs) were calculated using distinct genetic models. Heterogeneity between studies was detected by the χ2-based Q test. Additional analyses such as sensitivity analyses and publication bias were also performed. The rs1042522 polymorphism was not overall associated with ovarian cancer risk. But there was a borderline association in the heterozygote model (OR = 1.09, 95 % CI 0.99–1.21). Similar effects were observed in the subgroup of Caucasian population (the heterozygote model: OR = 1.11, 95 % CI 1.00–1.24). No significant heterogeneity and publication bias were revealed in this meta-analysis. This study provides statistical evidence that TP53 rs1042522 polymorphism may play a role in modulating risk of ovarian cancer. This observation requires further analysis of a larger study size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Weston, A., & Godbold, J. H. (1997). Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis. Environmental Health Perspectives, 105(Suppl 4), 919–926.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Havrilesky, L., et al. (2003). Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 21(20), 3814–3825.

    Article  CAS  PubMed  Google Scholar 

  3. Kmet, L. M., Cook, L. S., & Magliocco, A. M. (2003). A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer, 97(2), 389–404.

    Article  CAS  PubMed  Google Scholar 

  4. Bar, J. K., et al. (2009). Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: Correlation with clinicopathological parameters of tumors. International Journal of Gynecological Cancer, 19(8), 1322–1328.

    Article  PubMed  Google Scholar 

  5. Matlashewski, G. J., et al. (1987). Primary structure polymorphism at amino acid residue 72 of human p53. Molecular and Cellular Biology, 7(2), 961–963.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Beenken, S. W., et al. (1991). An intron binding protein is required for transformation ability of p53. Nucleic Acids Research, 19(17), 4747–4752.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Walker, K. K., & Levine, A. J. (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proceedings of the National Academy of Sciences of the United States of America, 93(26), 15335–15340.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Thomas, M., et al. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and Cellular Biology, 19(2), 1092–1100.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Shen, H., et al. (2002). P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Letters, 183(2), 123–130.

    Article  CAS  PubMed  Google Scholar 

  10. Granja, F., et al. (2004). Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Letters, 210(2), 151–157.

    Article  CAS  PubMed  Google Scholar 

  11. Koushik, A., Platt, R. W., & Franco, E. L. (2004). p53 codon 72 polymorphism and cervical neoplasia: A meta-analysis review. Cancer Epidemiology Biomarkers & Prevention, 13(1), 11–22.

    Article  CAS  Google Scholar 

  12. Francisco, G., et al. (2011). Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. International Journal of Cancer, 129(4), 920–930.

    Article  CAS  Google Scholar 

  13. Jemal, A., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71–96.

    Google Scholar 

  14. Li, T., et al. (2002). p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer, 95(12), 2571–2576.

    Article  CAS  PubMed  Google Scholar 

  15. Kang, S., et al. (2004). Association of p53 gene polymorphism with susceptibility to ovarian cancer. Zhonghua Fu Chan Ke Za Zhi, 39(11), 754–758.

    PubMed  Google Scholar 

  16. Santos, A. M., et al. (2006). Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. European Journal of Cancer, 42(7), 958–963.

    Article  CAS  PubMed  Google Scholar 

  17. Mantel, N., & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22(4), 719–748.

    CAS  PubMed  Google Scholar 

  18. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188.

    Article  CAS  PubMed  Google Scholar 

  19. Egger, M., et al. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Qie, M., Zhang, Y., & Wu, J. (2002). Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao, 33(2), 274–275.

    CAS  PubMed  Google Scholar 

  21. Ueda, M., et al. (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecologic Oncology, 100(1), 173–178.

    Article  CAS  PubMed  Google Scholar 

  22. Pegoraro, R. J., et al. (2003). P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. International Journal of Gynecological Cancer, 13(4), 444–449.

    Article  CAS  PubMed  Google Scholar 

  23. Agorastos, T., et al. (2004). P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. European Journal of Cancer Prevention, 13(4), 277–280.

    Article  CAS  PubMed  Google Scholar 

  24. Morari, E. C., et al. (2006). Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. Journal of Cancer Research and Clinical Oncology, 132(8), 521–528.

    Article  CAS  PubMed  Google Scholar 

  25. Schildkraut, J. M., et al. (2009). Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Research, 69(6), 2349–2357.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Buller, R. E., et al. (1997). The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Therapy, 4(4), 239–245.

    CAS  PubMed  Google Scholar 

  27. Peller, S., et al. (1999). Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncology Reports, 6(1), 193–197.

    CAS  PubMed  Google Scholar 

  28. Hogdall, E. V., et al. (2002). Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Research, 22(3), 1859–1864.

    CAS  PubMed  Google Scholar 

  29. Malisic, E. J., et al. (2013). Association of TP53 codon 72 polymorphism with susceptibility to ovarian carcinomas in Serbian women. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 166(1), 90–93.

    Article  CAS  PubMed  Google Scholar 

  30. Beckman, G., et al. (1994). Is p53 polymorphism maintained by natural selection? Human Heredity, 44(5), 266–270.

    Article  CAS  PubMed  Google Scholar 

  31. Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature, 358(6381), 15–16.

    Article  CAS  PubMed  Google Scholar 

  32. Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell, 88(3), 323–331.

    Article  CAS  PubMed  Google Scholar 

  33. Donehower, L. A. (1996). The p53-deficient mouse: a model for basic and applied cancer studies. Seminars in Cancer Biology, 7(5), 269–278.

    Article  CAS  PubMed  Google Scholar 

  34. Hollstein, M., et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Research, 22(17), 3551–3555.

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Wang, Y., et al. (2004). Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Human Mutation, 24(1), 21–34.

    Article  PubMed  Google Scholar 

  36. Harris, C. C., & Hollstein, M. (1993). Clinical implications of the p53 tumor-suppressor gene. New England Journal of Medicine, 329(18), 1318–1327.

    Article  CAS  PubMed  Google Scholar 

  37. Brekelmans, C. T. (2003). Risk factors and risk reduction of breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology, 15(1), 63–68.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Changle Western Road, Xi’an, 710032, Shaanxi, China

    Yanni Xi & Xiaoyan Xin

  2. Department of Gynecology and Obstetrics, Yulin Second Hospital, Yulin, 719000, Shaanxi, China

    Yanni Xi & Congrong Liu

Authors
  1. Yanni Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Congrong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoyan Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoyan Xin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xi, Y., Liu, C. & Xin, X. Association Between a Single Nucleotide Polymorphism in the TP53 Region and Risk of Ovarian Cancer. Cell Biochem Biophys 70, 1907–1912 (2014). https://doi.org/10.1007/s12013-014-0150-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0150-y

Keywords

Search

Navigation